Pharma News

The day in pharma, read in minutes.

Updated Nov 18, 2026

Latest news

11 stories
NewsNew

Nuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC

FDA grants neladalkib accelerated approval for ALK-positive NSCLC, triggering confirmatory trial and manufacturing scale-up obligations for Nuvalent.

Vaibhavi M.Nov 18, 2026Read more
Nuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC
NewsNew

Mandos Secures FDA Approval for Lembaz in Infantile-Onset NPC

FDA approves Lembaz for infantile-onset NPC using external control survival data, setting a precedent for rare disease regulatory strategy.

Vaibhavi M.Nov 18, 2026Read more
Mandos Secures FDA Approval for Lembaz in Infantile-Onset NPC
News

Viatris Completes $1.65B Acquisition of Pacira BioSciences

Viatris completes Pacira BioSciences acquisition, adding EXPAREL and iovera° and triggering NDA transfer and manufacturing integration work.

Vaibhavi M.Nov 17, 2026Read more
Viatris Completes $1.65B Acquisition of Pacira BioSciences
News

Greenwich LifeSciences Gets Two Abstracts Accepted for SABCS 2026

Greenwich LifeSciences secures two SABCS 2026 abstract acceptances for its Fast Track-designated GLSI-100 Phase III breast cancer immunotherapy trial.

Vaibhavi M.Nov 17, 2026Read more
Greenwich LifeSciences Gets Two Abstracts Accepted for SABCS 2026
News

Hikma Pharmaceuticals Appoints Ex-Cipla CEO Umang Vohra to Board

Hikma Pharmaceuticals names former Cipla CEO Umang Vohra to its Board and Audit Committee.

Vaibhavi M.Nov 17, 2026Read more
Hikma Pharmaceuticals Appoints Ex-Cipla CEO Umang Vohra to Board
News

Bioxcel Therapeutics Gains FDA Approval for First At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder

Bioxcel Therapeutics wins FDA approval for the first at-home agitation treatment, raising GMP and combination product compliance questions for CNS manufacturers.

Vaibhavi M.Nov 17, 2026Read more
Bioxcel Therapeutics Gains FDA Approval for First At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder
News

IDEAYA Biosciences Aligns with FDA on IDE849 Trial Strategy

IDEAYA Biosciences aligns with FDA on a dual-track IDE849 strategy: single-arm accelerated approval cohort plus concurrent Phase 3 in neuroendocrine carcinomas.

Vaibhavi M.Nov 17, 2026Read more
IDEAYA Biosciences Aligns with FDA on IDE849 Trial Strategy
News

FDA Approves Giredestrant Plus Everolimus for Breast Cancer

FDA approves Genentech's giredestrant plus everolimus for ESR1-mutated metastatic breast cancer, with FoundationOne Liquid CDx as mandatory companion diagnostic.

Vaibhavi M.Nov 17, 2026Read more
FDA Approves Giredestrant Plus Everolimus for Breast Cancer
News

Cue Biopharma Reports Phase 2 CSU Data and CUE-401 Dosing

Cue Biopharma's Phase 2 CSU data show durable IgE suppression 12 weeks post-dose; CUE-401 enters first-in-human dosing in Q3 2026.

Vaibhavi M.Nov 17, 2026Read more
Cue Biopharma Reports Phase 2 CSU Data and CUE-401 Dosing
News

Mankind Pharma Secures Exclusive India Rights for Ensartinib

Mankind Pharma secures exclusive India commercialisation rights for Betta's FDA-approved ALK inhibitor Ensartinib, targeting ALK-positive NSCLC patients.

Vaibhavi M.Nov 17, 2026Read more
Mankind Pharma Secures Exclusive India Rights for Ensartinib
News

Lantheus Meets Phase 3 Endpoints for TAUKLARIFY PET

Lantheus presents Phase 3 data for TAUKLARIFY tau-PET agent, meeting all sensitivity and specificity endpoints across 617 scans in early Alzheimer's disease.

Vaibhavi M.Nov 17, 2026Read more
Lantheus Meets Phase 3 Endpoints for TAUKLARIFY PET